{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:48:15Z","timestamp":1790819295356,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aims of the study were to assess the changes in 19\u2010years use of antibiotics (overall, by age, sex and geographical area) and of those classes deemed to be quality indicators for their consumption and to evaluate factors associated to antibiotic use. We analyzed drug prescription data collected in the administrative database of the Lombardy Region (Northern Italy) for outpatients aged 40+ years from 2000 to 2019. Logistic regression analyses were performed to evaluate the association between receiving at least one antibiotic prescription and year of observation, gender, age groups, area of residence, polypharmacy and hospitalizations in the index year. The prevalence of patients prescribed with antibiotics remained high from 2000 (33.8%) to 2019 (32.6%). Prevalence of use of second\u2010line choice antibiotics (penicillin combinations with beta\u2010lactamase inhibitors, third and fourth generation cephalosporins, macrolides) continued to increase, only fluoroquinolones decreased in 2019 (19%) comparing to 2018 (26%), at the time when the Italian Medicines Agency promulgated safety warnings. Females (OR 1.28, 95%CI 1.27\u20131.28), people living in Brescia (OR 1.24, 95%CI 1.24\u20131.25), those exposed to polypharmacy (OR 2.57, 95%CI 2.56\u20132.57) and those hospitalized 1 to 3 (OR 1.86, 95%CI 1.85\u20131.86) or more than 3 (OR 2.02, 95%CI 2.01\u20132.03) times a year had a statistically significant higher risk of receiving antibiotics. The high use of antibiotics over the study period further reinforces the need of impactful interventions, in order to improve the rational use of antibiotics and to reduce the risks of antimicrobial resistance. The differences outlined should be considered when monitoring and planning these interventions.<\/jats:p>","DOI":"10.1002\/prp2.878","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T09:59:42Z","timestamp":1634810382000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antibiotic use and associated factors in adult outpatients from 2000 to 2019"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6802-8710","authenticated-orcid":false,"given":"Carlotta","family":"Franchi","sequence":"first","affiliation":[{"name":"Department of Health Policy, Laboratory of Pharmacoepidemiology and Human Nutrition Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mandelli","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Laboratory of Pharmacoepidemiology and Human Nutrition Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Fortino","sequence":"additional","affiliation":[{"name":"Regional Health Ministry Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Nobili","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Laboratory of Pharmacoepidemiology and Human Nutrition Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2019.10.008"},{"key":"e_1_2_11_3_1","volume-title":"Antimicrobial resistance in the EU\/EEA (EARS\u2010Net) \u2010Annual Epidemiological Report 2019","author":"European Centre for Disease Prevention and Control","year":"2020"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"e_1_2_11_5_1","volume-title":"Antimicrobial Resistance. Tackling the Burden in the European Union. Briefing note for EU\/EEA countries","author":"Organisation for Economic Co\u2010operation and Development (OECD) and European Centre for Disease Prevention and Control (ECDC)","year":"2019"},{"key":"e_1_2_11_6_1","unstructured":"Italian Ministry of Health.National Action Plan on Antimicrobial Resistance 2017\u20102020.http:\/\/www.salute.gov.it\/portale\/documentazione\/p6_2_5_1.jsp?lingua=italiano&id=362"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16201"},{"issue":"1","key":"e_1_2_11_8_1","first-page":"133","article-title":"Unnecessary antibiotic prescribing in US ambulatory care settings, 2010\u20132015","volume":"72","author":"Hersh AL","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"e_1_2_11_9_1","first-page":"401","article-title":"Inappropriate antibiotic prescription for respiratory tract indications: most prominent in adult patients","volume":"32","author":"Dekker AR","year":"2015","journal-title":"Fam Pract"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4151"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12610"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16010027"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.08.018"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02713-1"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0129-1"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw054"},{"issue":"9","key":"e_1_2_11_17_1","first-page":"1308","article-title":"US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011","volume":"60","author":"Hicks LA","year":"2015","journal-title":"Clin Infect Dis"},{"key":"e_1_2_11_18_1","volume-title":"National Report on Medicines use in Italy","author":"The Medicines Utilisation Monitoring Centre","year":"2020"},{"key":"e_1_2_11_19_1","unstructured":"Lombardy Region. Agenzie di Tutela della Salute (ATS).https:\/\/www.regione.lombardia.it\/wps\/portal\/istituzionale\/HP\/DettaglioServizio\/servizi\u2010e\u2010informazioni\/Cittadini\/salute\u2010e\u2010prevenzione\/agenzie\u2010di\u2010tutela\u2010della\u2010salute\/ser\u2010aziende\u2010sanitarie\u2010locali\u2010sal\/agenzie\u2010tutela\u2010salute"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3938"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1621-6"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-202528"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2124"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1495-7"},{"key":"e_1_2_11_25_1","unstructured":"European Medicines Agency.Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics.2019.https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone\u2010fluoroquinolone\u2010article\u201031\u2010referral\u2010disabling\u2010potentially\u2010permanent\u2010side\u2010effects\u2010lead_en.pdf"},{"key":"e_1_2_11_26_1","unstructured":"European Centre for Disease Prevention and Control.Quality indicators for antibiotic. Consumption in the community.https:\/\/www.ecdc.europa.eu\/en\/antimicrobial\u2010consumption\/database\/quality\u2010indicators"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2006.021121"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"issue":"1","key":"e_1_2_11_29_1","first-page":"S1","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2021\/22: introduction and other protein targets","volume":"178","author":"Alexander SP","year":"2021","journal-title":"Br J Pharmacol"},{"key":"e_1_2_11_30_1","unstructured":"European Centre for Disease Prevention and Control.Antimicrobial consumption \u2010 Annual Epidemiological Report for 2019.https:\/\/www.ecdc.europa.eu\/en\/publications\u2010data\/surveillance\u2010antimicrobial\u2010consumption\u2010europe\u20102019"},{"key":"e_1_2_11_31_1","volume-title":"The 2019 WHO AWaRe classification of antibiotics for evaluation and monitoring of use","author":"World Health Organization","year":"2019"},{"key":"e_1_2_11_32_1","unstructured":"Italian Agency of Medicine.Azithromycinin the treatmentof adult patients with COVID\u201019.2020.https:\/\/www.aifa.gov.it\/documents\/20142\/1267737\/Azithromycin_EN_05.05.2020.pdf"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1983"},{"key":"e_1_2_11_34_1","unstructured":"Centers for disease Control and Prevention.Fluoroquinolones.https:\/\/arpsp.cdc.gov\/profile\/antibiotic\u2010use\/214#comparing\u2010antibiotics\u2010classes"},{"key":"e_1_2_11_35_1","unstructured":"Centers for disease Control and Prevention.Inappropriate prescribing of antibiotics: the example of fluoroquinolones.2018.https:\/\/arpsp.cdc.gov\/story\/inappropriate\u2010prescribing\u2010antibiotics\u2010fluoroquinolones"},{"key":"e_1_2_11_36_1","unstructured":"US Food and Drug Administration.FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects.2016.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010fda\u2010updates\u2010warnings\u2010oral\u2010and\u2010injectable\u2010fluoroquinolone\u2010antibiotics"},{"key":"e_1_2_11_37_1","unstructured":"European Medicines Agency.Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics.2018.https:\/\/www.ema.europa.eu\/en\/news\/disabling\u2010potentially\u2010permanent\u2010side\u2010effects\u2010lead\u2010suspension\u2010restrictions\u2010quinolone\u2010fluoroquinolone"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0089-8"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0751-2"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.1154"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3716"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.09.003"},{"key":"e_1_2_11_43_1","unstructured":"Italian Data Protection Authority.General authorisation to process personal data for scientific research purposes\u20141 March 2012 [1884019]. doi:10.1094\/PDIS\u201011\u201011\u20100999\u2010PDN"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.878","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:45:40Z","timestamp":1693215940000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/prp2.878"],"URL":"https:\/\/doi.org\/10.1002\/prp2.878","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"2021-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00878"}}